Brandon Lucke-Wold was born and raised in Colorado Springs, CO. He graduated magna cum laude with a BS in Neuroscience and distinction in honors from Baylor University. He completed his MD/PhD, Master’s in Clinical and Translational Research, and the Global Health Track at West Virginia University School of Medicine. His research focus was on traumatic brain injury, neurosurgical simulation, and stroke. At West Virginia University, he also served as a health coach for the Diabetes Prevention and Management program in Morgantown and Charleston, WV, which significantly improved health outcomes for participants. In addition to his research and public health projects, he is a co-founder of the biotechnology company SwiftScience, the pharmaceutical company TauGen, and was a science advocate on Capitol Hill through the Washington Fellow’s program.
He has also served as president of the WVU chapters for the American Association of Pharmaceutical Scientists, Neurosurgery Interest group, and Erlenmeyer Initiative Entrepreneur group. In addition, he has served as vice president for the graduate student neuroscience interest group, Nu Rho Psi Honor Society, and medical students for global health. He was an active member of the Gold Humanism Honor Society and Alpha Omega Alpha Honor Society. He is currently President of the UF House Staff Council, Chair of North American Spine Society Early Career Member Section, Former Chair of the UF Quality Improvement Committee, on the Board of Directors for the Alachua County Medical Society, and resident board member for the Florida Medical Association. He is married to Noelle Lucke-Wold and has two children. As a family, they enjoy running with their dogs, kayaking, and traveling. In his spare time, Brandon frequently runs half marathons and 10ks together with is wife. Brandon also enjoys reading, playing piano, discussing philosophy, and playing chess. He is currently a Pgy7 neurosurgery resident at University of Florida and will be completing endovascular fellowship 2025/2026 academic year. He has transitioned to research on treatment of vasospasm by targeting the neuroinflammatory cascade following subarachnoid hemorrhage. He was awarded the Dempsey Cerebrovascular Research Fellowship, NSTP Year 1 Fellowship, Van Wagenen Fellowship, R25 Grant, SNIS Fellowship, and NREF Research Grant in addition to multiple research presentation awards.